Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy.

Fantasia KL, Steenkamp DW

Journal of the Endocrine Society3 Oct 2019Cited by 17 (Europe PMC)

PMID31737858PMCIDPMC6846329DOI10.1210/js.2019-00278PepBankPUB-31737858

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanCase report or seriesEfficacy outcome
A woman with HNF1A MODY maintained optimal glycemic control on dulaglutide monotherapy for >12 months.
In plain wordsA woman with HNF1A MODY maintained optimal blood sugar control on dulaglutide alone for >12 months.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableGlycemic control
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · >12 monthsAs given in this study (human).
Source sentences
Summary
More than a decade from diabetes diagnosis, she has maintained optimal glycemic control without hypoglycemia for >12 months while receiving GLP-1 RA therapy alone.
1 context sentence(design, population, supporting numbers)
Summary · context
We present the case of a 27-year-old woman with inadequately controlled HNF1A maturity-onset diabetes of the young (MODY) who was successfully transitioned from sulfonylurea therapy to once-weekly monotherapy with dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).
Report a problemFND-3173785801
02HumanCase report or seriesSafety outcome
A woman with HNF1A MODY had no hypoglycemia during >12 months of dulaglutide monotherapy.
In plain wordsA woman with HNF1A MODY had no low blood sugar during >12 months of dulaglutide alone.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHypoglycemia
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · >12 monthsAs given in this study (human).
Source sentences
Summary
More than a decade from diabetes diagnosis, she has maintained optimal glycemic control without hypoglycemia for >12 months while receiving GLP-1 RA therapy alone.
1 context sentence(design, population, supporting numbers)
Summary · context
We present the case of a 27-year-old woman with inadequately controlled HNF1A maturity-onset diabetes of the young (MODY) who was successfully transitioned from sulfonylurea therapy to once-weekly monotherapy with dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).
Report a problemFND-3173785802

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.